Literature DB >> 22995543

A comparison of anesthetic regimens using etomidate and propofol in patients undergoing first-trimester abortions: double-blind, randomized clinical trial of safety and efficacy.

Jing Wu1, Shanglong Yao, Zhouyang Wu, Zhiling Wu, Shujuan Chu, Geqing Xia, Feitao Deng.   

Abstract

BACKGROUND: This prospective study compared the safety, recovery time and side effects of six distinct general anesthesia regimens for first-trimester surgical abortion. STUDY
DESIGN: Two hundred forty women scheduled for surgical abortion at 6 to 8 weeks of gestation were randomized into three groups (n=40) of propofol: group P (2 mg/kg propofol alone), group PF (2 mg/kg propofol+1 mcg/kg fentanyl), group PMF (2 mg/kg propofol+1 mcg/kg fentanyl+0.02 mg/kg midazolam) and three groups (n=40) of etomidate: group E (0.2 mg/kg etomidate alone), group EF (0.2 mg/kg etomidate+1 mcg/kg fentanyl) and group EMF (0.2 mg/kg etomidate+1 mcg/kg fentanyl+0.02 mg/kg midazolam). Vital signs including pulse oxygen saturation (SpO2), mean arterial pressure (MAP) and heart rate were recorded as the primary outcomes. The recovery time and side effects were recorded as secondary outcomes.
RESULTS: During induction, SpO2 and MAP decreased significantly in all the three groups of propofol and were significantly lower than those in the groups of etomidate. Mean recovery times to both eye opening and to obeying commands were significantly shorter in group PF than those in groups P and PMF, while there were no significant differences among the three groups of etomidate. Compared with the etomidate groups, the incidence of injection-induced pain was significantly higher, while the scores of myoclonus and postoperative nausea and vomiting were lower, in the three propofol groups. Moreover, myoclonus scores as well as nausea and vomiting scores were lower in group EMF than in groups E and EF.
CONCLUSIONS: The results of this study suggest that (a) etomidate is much safer than propofol for first-trimester surgical abortions and (b) using a lower dose of etomidate, supplemented with fentanyl and midazolam, is more beneficial than the use of etomidate with or without fentanyl in reducing adverse effects like myoclonus and postoperative nausea and vomiting.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995543     DOI: 10.1016/j.contraception.2012.08.014

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Safety and efficacy of etomidate and propofol anesthesia in elderly patients undergoing gastroscopy: A double-blind randomized clinical study.

Authors:  Qing-Tao Meng; Chen Cao; Hui-Min Liu; Zhong-Yuan Xia; Wei Li; Ling-Hua Tang; Rong Chen; Meng Jiang; Yang Wu; Yan Leng; Chris C Lee
Journal:  Exp Ther Med       Date:  2016-06-24       Impact factor: 2.447

2.  Etomidate plus propofol versus propofol alone for sedation during gastroscopy: a randomized prospective clinical trial.

Authors:  Xiang Zhou; Bi-Xi Li; Li-Min Chen; Jun Tao; Sui Zhang; Meng Ji; Ming-Chun Wu; Min Chen; Yan-Hui Zhang; Guo-Shen Gan; Xiao-Yang Song
Journal:  Surg Endosc       Date:  2016-03-22       Impact factor: 4.584

3.  Sedation and analgesia with fentanyl and etomidate for intrathecal injection in childhood leukemia patients.

Authors:  Chun-Hui Yang; Xin Tian; Hai-Bin Yin; Xiao-Hui Gao; Na Li
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

4.  Pain management of surgical abortion using transcutaneous acupoint electrical stimulation: An orthogonal prospective study.

Authors:  Zedong Wang; Yong Chen; Chong Chen; Liang Zhao; Pinjie Chen; Linchai Zeng; Wenxia Xie
Journal:  J Obstet Gynaecol Res       Date:  2018-07       Impact factor: 1.730

5.  Relationship between UGT1A9 gene polymorphisms, efficacy, and safety of propofol in induced abortions amongst Chinese population: a population-based study.

Authors:  Ying-Bin Wang; Rong-Zhi Zhang; Sheng-Hui Huang; Shu-Bao Wang; Jian-Qin Xie
Journal:  Biosci Rep       Date:  2017-10-24       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.